Drug Profile
Research programme: cancer immunotherapy - NTRC/Vipergen
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Netherlands Translational Research Center; Vipergen ApS
- Class Antineoplastics; Immunotherapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for research development in Cancer in Denmark
- 28 Jan 2020 No recent reports of development identified for research development in Cancer in Netherlands
- 04 Dec 2015 Early research in Cancer in Netherlands, Denmark (unspecified route)